Learning Module Overview for:
Novel Anticancer Agents and Their Clinical Implications

View the complete offering
of Learning Modules

Registration Required
To access CME activities and to view your personalized CME Profile page, which tracks completed learning modules, post-test scores and CME credits earned, and allows you to download printable CME certificates.

Send us your comments
We welcome your feedback and / or questions related to the educational content provided through Mechanisms in Myeloma and Related Diseases.

Release date: December 31, 2008
Expiration date: December 31, 2009

Click here to view Technical Requirements

This learning activity has been designated for 1.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in this activity.

Target Audience
This learning activity is intended for medical oncologists, hematologists, stem cell transplant physicians, and other interested healthcare professionals who treat and manage myeloma and related diseases in the hematology/oncology and transplant patient settings.

Learning Objectives
Upon completion of this education program the participant should be able to:

  • Discuss the novel immunomodulatory agents and proteasome inhibitors recently approved for treatment of multiple myeloma;
  • Cite and summarize pivotal clinical trial data concerning bortezomib, thalidomide, and lenalidomide;
  • Describe the investigative efforts underway in evaluation of HSP90 inhibitors, Akt inhibitors, anti-CS1 monoclonal antibodies, anti–IL-6 monoclonal antibodies, and new proteasome inhibitors and immunomodulatory agents, as well as their potential role in combination with standard therapeutic agents for myeloma.

Donna M. Weber, MD
Associate Professor, Lymphoma/Myeloma
MD Anderson Cancer Center
Houston, Texas

Medical Writers
James W. Clendening
Toronto, Ontario

Marie Sabo Recine
Hamilton Square, New Jersey

Disclosure of Financial Interests
As an accredited provider of continuing medical education, Imedex, LLC is required to ask authors to disclose any real or apparent conflict of interest they may have as related to the content of their chapter(s). The existence of commercial or financial interests of speakers related to the subject matter of their chapter(s) should not be construed as implying bias or decreasing the value of their chapter(s). However, the disclosure should help participants form their own judgments.

All authors were independently selected by the organizing committee. Those authors who disclosed affiliations or financial interests with the commercial organizations involved with products, to which they may refer are listed below.
  1. grant research
  2. consultant
  3. speaker's bureau
  4. stock shareholder
  5. other support

Dr Donna M. Weber
Supporters of this activity:

Other affiliations:

Medical Writers
James W. Clendening
Does not report any affiliations with commercial organizations.

Marie Sabo Recine
Does not report any affiliations with commercial organizations.

Imedex, LLC Staff Disclosure of Financial Relationships
Imedex, LLC is a subsidiary of AmerisourceBergen Specialty Group, which is a subsidiary of AmerisourceBergen Company. All Imedex staff members, except for the following, who are in a position to control the content of this activity, have no financial relationships with any commercial interests that are relevant to this activity:

Keith Steward, MD, MBA, owns shares of Pfizer Inc and Johnson & Johnson, as well as stock options for AmerisourceBergen.

Chris Bolwell owns shares of GlaxoSmithKline and stock options for AmerisourceBergen.

Bradley Bongiovanni, ND, Becky Lynch, RN, Emily Geiger, and Don Harting, MA, ELS own stock options for AmerisourceBergen.

Imedex, LLC is an independent provider of continuing medical education. Imedex, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA has regulatory authority.

Disclosure of Unapproved Uses and Investigational Drugs
This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the US Food and Drug Administration (FDA) and/or other national regulatory agencies in the United States and other countries. Participants in the United States are encouraged to consult the FDA-approved product labeling for any drug or device mentioned in this program before use. Participants from other countries should consult with their respective regulatory authorities.

Statement of Commercial Support
The following companies have provided unrestricted educational grants in support of this activity: Celgene Corporation, Millenium Pharmaceuticals Inc and Novartis Pharma US

(*Please check this box to proceed - required)

About Us | Contact Us | Terms of Use | Privacy Policy | Technical Requirements | Site Map | Help